KP-2033

Pembrolizumab

Home » Antibody » Pembrolizumab

Background

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.?It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds.It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,?becoming the first approved therapy against PD-1.?In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.

Specifications

Catalog Number:
KP-2033
Cell Line Name:
Pembrolizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PD1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Longoria TC, Tewari KS: Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53. 2.Poole RM: Pembrolizumab: first global approval. Drugs. 2014 Oct;74(16):1973-81. Longoria TC, Tewari KS: Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1247-53.
Please enable JavaScript in your browser to complete this form.